Results 1 to 10 of about 141,293 (340)
A PURIFICATION OF VENOM PHOSPHODIESTERASE
Journal of Biological Chemistry, 1952 For purposes of analysis of polynucleotides, it is desirable to have a phosphodiesterase, substantially free of 5-nucleotidase or other phosphatase activity. The presence of a phosphodiesterase in a wide variety of snake venoms was demonstrated by Gullan and Jackson (1). These venoms were found also to contain a potent 5-nucleotidase, but were free of
Sinsheimer, Robert L., Koerner, James F.
openaire +5 more sources
Alterations of Phosphodiesterases in Adrenocortical Tumors [PDF]
Frontiers in Endocrinology, 2016 Alterations in the cyclic (c) AMP-dependent signaling pathway have been implicated in the majority of benign adrenocortical tumors (ACTs) causing Cushing syndrome (CS).
Fady Hannah-Shmouni +2 more
doaj +4 more sources
Clinical Implication of Phosphodiesterase-4-Inhibition
International Journal of Molecular Sciences, 2022 The pleiotropic function of 3′,5′-cyclic adenosine monophosphate (cAMP)-dependent pathways in health and disease led to the development of pharmacological phosphodiesterase inhibitors (PDE-I) to attenuate cAMP degradation.
M. Schick, N. Schlegel
semanticscholar +1 more source
Frontiers in Aging Neuroscience, 2022 Alzheimer’s disease (AD) is the most common form of dementia and is ranked as the 6th leading cause of death in the US. The prevalence of AD and dementia is steadily increasing and expected cases in USA is 14.8 million by 2050.
Jianwen Sheng +6 more
doaj +1 more source
Phosphodiesterase inhibitors [PDF]
British Journal of Pharmacology, 2006 Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this ...
Boswell-Smith, V, Spina, D, Page, C P
openaire +4 more sources
Frontiers in Pharmacology, 2020 Leishmaniasis are group of neglected diseases with worldwide distribution that affect about 12 million people. The current treatment is limited and may cause severe adverse effects, and thus, the search for new drugs more effective and less toxic is ...
Dahara Keyse Carvalho Silva +13 more
doaj +1 more source
Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
Frontiers in Pharmacology, 2020 Mucociliary clearance is an essential airway defense mechanism dependent predominantly on the proper ciliary function and mucus rheology. The crucial role of cilia is evident in `a variety of respiratory diseases, as the ciliary dysfunction is associated
Marta Joskova, Juraj Mokry, Sona Franova
doaj +1 more source
Kefir protects the liver against high fructose corn syrup induced phosphodiesterase hyperactivity
Türk Biyokimya Dergisi, 2022 Phosphodiesterases (PDEs) mediate several physiological activities, and alterations in PDE expressions might cause conflicts between functional and clinical effects.
Pektaş Mehmet Bilgehan +7 more
doaj +1 more source
Use of a Fission Yeast Platform to Identify and Characterize Small Molecule PDE Inhibitors
Frontiers in Pharmacology, 2022 Cyclic nucleotide phosphodiesterases (PDEs) have been proven to be targets for which highly selective and potent drugs can be developed. Mammalian genomes possess 21 genes whose products are pharmacologically grouped into 11 families; however related ...
Charles S. Hoffman
doaj +1 more source
Phosphodiesterases in neurodegenerative disorders [PDF]
IUBMB Life, 2012 AbstractCyclic nucleotide phosphodiesterases (PDEs) are responsible for the breakdown of cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). As such, they are crucial regulators of levels of cyclic nucleotide‐mediated signaling.
Jos Prickaerts, Eva Bollen
openaire +3 more sources